In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 349-359

  Toledo, Rodrigo A ^a   Qin, Yuejuan ^a   Srikantan, Subramanya ^a   Morales, Nicole Paes ^a   Li, Qun ^a   Deng, Yilun ^a   Kim, Sang Woo ^a,e   Pereira, Maria Adelaide A ^c   Toledo, Sergio P A ^c   Su, Xiaoping ^d   Aguiar, Ricardo C T ^a,b   Dahia, Patricia L M ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Pusan National University   (South Korea)

Author keywords

Cancer; EPAS1; HIF2A; Hypoxia; Mutations; Paraganglioma; Pheochromocytoma; Somatic

Indexed keywords

COMPLEMENTARY DNA; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL MUTANT; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; FAMILIAL CANCER; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LATENT PERIOD; MOUSE; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; SOMATIC MUTATION; STABLE EXPRESSION; STEM CELL; TRANSACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT;

CANCER; EPAS1; HIF2A; HYPOXIA; MUTATIONS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SOMATIC;

ADRENAL GLAND NEOPLASMS; AGED; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHILD; FEMALE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MUTATION; PARAGANGLIOMA; PC12 CELLS; PHEOCHROMOCYTOMA; RATS; TUMOR BURDEN;

EID: 84879468754     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0101     Document Type: Article

References (30)

1. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A et al. 2005 Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8 131-141. (doi:10.1016/j.ccr.2005.07.003)
2. Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J et al. 2011 Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics 20 3974-3985. (doi:10.1093/hmg/ddr324)
3. Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, Inglada-Perez L, de Cubas AA, Amar L, Barontini M et al. 2012 MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clinical Cancer Research 18 2828-2837. (doi:10.1158/1078-0432.CCR-12-0160)
4. Comino-Mendez I, de Cubas AA, Bernal C, Alvarez-Escola C, Sanchez-Malo C, Ramirez-Tortosa CL, Pedrinaci S, Rapizzi E, Ercolino T, Bernini G et al. 2013 Tumoral EPAS1 (HIF2A)mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics. (doi:10.1093/hmg/ddt069)
5. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS et al. 2005 A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 1 72-80. (doi:10.1371/journal.pgen.0010008)
6. Favier J, Buffet A & Gimenez-Roqueplo AP 2012 HIF2A mutations in paraganglioma with polycythemia. New England Journal of Medicine 367 2161 (author reply 2161-2162). (doi:10.1056/NEJMc1211953)
7. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P, Rotig A & Jeunemaitre X 2001 The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. American Journal of Human Genetics 69 1186-1197. (doi:10. 1086/324413)
8. Gordan JD, Bertout JA, Hu CJ, Diehl JA & Simon MC 2007 HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11 335-347. (doi:10.1016/j.ccr.2007.02.006)
9. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L et al. 2011 Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genetics 43 875-878. (doi:10.1038/ng.907)
10. Hillier LW, Marth GT, Quinlan AR, Dooling D, Fewell G, Barnett D, Fox P, Glasscock JI, Hickenbotham M, Huang W et al. 2008 Whole-genome sequencing and variant discovery in C. elegans. Nature Methods 5 183-188. (doi:10.1038/nmeth. 1179)
11. Jafri M & Maher ER 2012 The genetics of phaeochromocytoma: using clinical features to guide genetic testing. European Journal of Endocrinology 166 151-158. (doi:10.1530/EJE-11-0497)
12. Kaelin WG, Jr & Ratcliffe PJ 2008 Oxygen sensing bymetazoans: the central role of the HIF hydroxylase pathway. Molecular Cell 30 393-402. (doi:10.1016/j.molcel.2008.04.009)
13. Kondo K, Klco J, Nakamura E, Lechpammer M & Kaelin WG, Jr 2002 Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 237-246. (doi:10.1016/S1535-6108(02)00043-0)
14. Kondo K, Kim WY, Lechpammer M & Kaelin WG, Jr 2003 Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biology 1 E83. (doi:10.1371/journal.pbio.0000083)
15. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Jr et al. 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 155-167. (doi:10.1016/j.ccr.2005.06.015)
16. Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K & Prchal JT 2012 A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Journal of Molecular Medicine 91 507-512. (doi:10.1007/s00109-012-0967-z)
17. Marth GT, Korf I, Yandell MD, Yeh RT, Gu Z, Zakeri H, Stitziel NO, Hillier L, Kwok PY & Gish WR 1999 A general approach to single-nucleotide polymorphism discovery. Nature Genetics 23 452-456. (doi:10.1038/70570)
18. Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC et al. 2010 HIF-2α deletion promotes Kras-driven lung tumor development. PNAS 107 14182-14187. (doi:10.1073/pnas.1001296107)
19. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG, Jr & Pavletich NP 2002 Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296 1886-1889. (doi:10.1126/science.1073440)
20. Pacak K, Jochmanova I, Prodanov T, Yang C, Merino M, Fojo T, Prchal JT, Tischler AS, Lechan RM & Zhuang Z 2013 A new syndrome of paraganglioma and somatostatinoma associated with polycythemia. Journal of Clinical Oncology.
21. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF & Lee FS 2006 A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. PNAS 103 654-659. (doi:10.1073/pnas.0508423103)
22. Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S et al. 2009 HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. PNAS 106 16805-16810. (doi:10.1073/pnas. 0904606106)
23. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F et al. 2010 Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics 42 229-233. (doi:10.1038/ng.533)
24. Qing G & Simon MC 2009 Hypoxia inducible factor-2α: a critical mediator of aggressive tumor phenotypes. Current Opinion in Genetics & Development 19 60-66. (doi:10.1016/j.gde.2008.12.001)
25. Rai D, Kim SW, McKeller MR, Dahia PL & Aguiar RC 2010 Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis. PNAS 107 3111-3116. (doi:10.1073/pnas.0910667107)
26. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL & Ratcliffe PJ 2005 Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 25 5675-5686. (doi:10.1128/MCB.25.13.5675-5686.2005)
27. Selak MA, Armour SM, Mackenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB & Gottlieb E 2005 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7 77-85. (doi:10.1016/j.ccr.2004. 11.022)
28. Semenza GL 2012 Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in Pharmacological Sciences 33 207-214. (doi:10.1016/j.tips.2012.01.005)
29. Yan Q, Bartz S, Mao M, Li L & Kaelin WG, Jr 2007 The hypoxia-inducible factor 2α N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis In vivo. Molecular and Cellular Biology 27 2092-2102. (doi:10.1128/MCB.01514-06)
30. Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT & Pacak K 2012 Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. New England Journal of Medicine 367 922-930. (doi:10.1056/NEJMoa1205119)